Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?

Depression and Anxiety

Volumn 28, Issue 11, 2011, Pages 989-998

  Gaynes, Bradley N ^a   Farley, Joel F ^b   Dusetzina, Stacie B ^c   Ellis, Alan R ^b   Hansen, Richard A ^d   Miller, William C ^e   Stürmer, Til ^e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d AUBURN UNIVERSITY   (United States)

^e IL   (United States)

Author keywords

antidepressant; depression; medication selection; propensity score; symptom cluster

Indexed keywords

AMFEBUTAMONE; BUSPIRONE; CITALOPRAM; SERTRALINE; VENLAFAXINE;

ADULT; AGED; ARTICLE; DATA ANALYSIS; DEPRESSION; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; REMISSION; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; BIAS (EPIDEMIOLOGY); BUPROPION; BUSPIRONE; CLUSTER ANALYSIS; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DOPAMINE UPTAKE INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN RECEPTOR AGONISTS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 81255209348     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20898     Document Type: Article

References (39)

1. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008; 149: 734-750.
2. Mauskopf JA, Simon GE, Kalsekar A, Nimsch C, Dunayevich E, Cameron A,. Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder. Depress Anxiety 2009; 26: 83-97.
3. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008; 165: 342-351. (Pubitemid 351704490)
4. Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF,. Major depressive subtypes and treatment response. Biol Psychiatry 1997; 42: 568-576. (Pubitemid 27425475)
5. Henningsen P, Zimmermann T, Sattel H,. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med 2003; 65: 528-533. (Pubitemid 36900246)
6. Matza LS, Revicki DA, Davidson JR, Stewart JW,. Depression with atypical features in the national comorbidity survey: classification, description, and consequences. Arch Gen Psychiatry 2003; 60: 817-826. (Pubitemid 36960913)
7. Smith GR,. The epidemiology and treatment of depression when it coexists with somatoform disorders, somatization, or pain. Gen Hosp Psychiatry 1992; 14: 265-272.
8. Souery D, Papakostas GI, Trivedi MH,. Treatment-resistant depression. J Clin Psychiatry 2006; 67: 16-22. (Pubitemid 44078108)
9. Berman RM, Narasimhan M, Charney DS,. Treatment-refractory depression: definitions and characteristics. Depress Anxiety 1997; 5: 154-164. (Pubitemid 28082224)
10. Charney DS, Nelson JC, Quinlan DM,. Personality traits and disorder in depression. Am J Psychiatry 1981; 138: 1601-1604. (Pubitemid 12242826)
11. Shea MT, Pilkonis PA, Beckham E, et al. Personality disorders and treatment outcome in the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry 1990; 147: 711-718. (Pubitemid 20188508)
12. Thompson LW, Gallagher D, Czirr R,. Personality disorder and outcome in the treatment of late-life depression. J Geriatr Psychiatry 1988; 21: 133-153.
13. Zimmerman M, Posternak M, Friedman M, et al. Which factors influence psychiatrists' selection of antidepressants? Am J Psychiatry 2004; 161: 1285-1289. (Pubitemid 38859180)
14. Kornstein SG, Schneider RK,. Clinical features of treatment-resistant depression. J Clin Psychiatry 2001; 62: 18-25.
15. Kavoussi RJ, Segraves RT, Hughes AR, Ascher JA, Johnston JA,. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997; 58: 532-537. (Pubitemid 28100273)
16. Weihs KL, Settle Jr EC, Batey SR, Houser TL, Donahue RM, Ascher JA,. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000; 61: 196-202. (Pubitemid 30214516)
17. American Psychiatric Association. Practice guideline for the treatment of patients with major depression (revision). Am J Psychiatry 2000; 157: 1-45.
18. Schoevers RA, Van HL, Koppelmans V, Kool S, Dekker JJ,. Managing the patient with co-morbid depression and an anxiety disorder. Drugs 2008; 68: 1621-1634.
19. Rush AJ, Wisniewski SR, Warden D, et al. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 2008; 65: 870-880.
20. Rush A, Fava M, Wisniewski S, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004; 25: 119-142. (Pubitemid 38230109)
21. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 2003; 26: 457-494.x. (Pubitemid 36583573)
22. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). J Am Med Assoc 2003; 289: 3095-3105. (Pubitemid 37432885)
23. Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression:a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial report. Biol Psychiatry 2006; 59: 493-501. (Pubitemid 43320536)
24. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54: 573-583. (Pubitemid 37289444)
25. Hamilton M,. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
26. Hamilton M,. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
27. Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51: 1171-1178. (Pubitemid 28527173)
28. Endicott J, Nee J, Harrison W, Blumenthal R,. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 1993; 29: 321-326. (Pubitemid 23311543)
29. Wisniewski SR, Rush AJ, Bryan CP, et al. for the, S.I. Comparison of quality of life measures in a depressed population. J Nerv Ment Dis 2007; 195: 219-225. (Pubitemid 46673542)
30. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996; 26: 477-486. (Pubitemid 26142491)
31. Fava M, Alpert JE, Carmin CN, et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med 2004; 34: 1299-1308. (Pubitemid 39517160)
32. Novick JS, Stewart JW, Wisniewski SR, et al. Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. J Clin Psychiatry 2005; 66: 1002-1011. (Pubitemid 41191792)
33. Gaynes BN, Rush AJ, Trivedi M, et al. A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the STAR*D clinical trial. Gen Hosp Psychiatry 2005; 27: 87-96. (Pubitemid 40348772)
34. SAS Institute Inc. SAS/STAT 9.2 User's Guide. Cary, NC: SAS Institute Inc; 2008.
35. Allison P,. Missing Data. Sage University Papers Series on Quantitative Applications in the Social Sciences. Thousand Oaks, CA: Sage; 2002.
36. Graham JW,. Missing data analysis: making it work in the real world. Annu Rev Psychol 2009; 60: 549-576.
37. Robbins AS, Chao SY, Fonseca VP,. What's the relative risk? A method to directly estimate risk ratios in cohort studies of common outcomes. Ann Epidemiol 2002; 12: 452-454.
38. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354: 1243-1252.
39. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354: 1231-1242.